JP2013534536A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013534536A5 JP2013534536A5 JP2013519726A JP2013519726A JP2013534536A5 JP 2013534536 A5 JP2013534536 A5 JP 2013534536A5 JP 2013519726 A JP2013519726 A JP 2013519726A JP 2013519726 A JP2013519726 A JP 2013519726A JP 2013534536 A5 JP2013534536 A5 JP 2013534536A5
- Authority
- JP
- Japan
- Prior art keywords
- batch
- laquinimod
- pharmaceutically acceptable
- ethylaniline
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OJGMBLNIHDZDGS-UHFFFAOYSA-N N-Ethylaniline Chemical compound CCNC1=CC=CC=C1 OJGMBLNIHDZDGS-UHFFFAOYSA-N 0.000 claims description 40
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 claims description 31
- 229960004577 laquinimod Drugs 0.000 claims description 31
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- BZKCTVZVKAXVFH-UHFFFAOYSA-N 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenylquinoline-3-carboxamide Chemical compound O=C1N(C)C2=CC=CC(Cl)=C2C(O)=C1C(=O)NC1=CC=CC=C1 BZKCTVZVKAXVFH-UHFFFAOYSA-N 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- FTBWKSJUFWRKGL-UHFFFAOYSA-N 5-chloro-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxylic acid Chemical compound C1=CC(Cl)=C2C(O)=C(C(O)=O)C(=O)N(C)C2=C1 FTBWKSJUFWRKGL-UHFFFAOYSA-N 0.000 claims description 2
- 150000003857 carboxamides Chemical class 0.000 claims description 2
- 150000004702 methyl esters Chemical class 0.000 claims description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 2
- 239000008247 solid mixture Substances 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 229940088679 drug related substance Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39926410P | 2010-07-09 | 2010-07-09 | |
| US61/399,264 | 2010-07-09 | ||
| PCT/US2011/043391 WO2012006544A1 (en) | 2010-07-09 | 2011-07-08 | 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015204932A Division JP2016053049A (ja) | 2010-07-09 | 2015-10-16 | ５−クロロ−４−ヒドロキシ−１−メチル−２−オキソ−ｎ−フェニル−１，２−ジヒドロキノリン−３−カルボキサミドと、その塩及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013534536A JP2013534536A (ja) | 2013-09-05 |
| JP2013534536A5 true JP2013534536A5 (enExample) | 2014-08-21 |
| JP5934202B2 JP5934202B2 (ja) | 2016-06-15 |
Family
ID=45439027
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519726A Expired - Fee Related JP5934202B2 (ja) | 2010-07-09 | 2011-07-08 | ５−クロロ−４−ヒドロキシ−１−メチル−２−オキソ−ｎ−フェニル−１，２−ジヒドロキノリン−３−カルボキサミドと、その塩及びその使用 |
| JP2015204932A Pending JP2016053049A (ja) | 2010-07-09 | 2015-10-16 | ５−クロロ−４−ヒドロキシ−１−メチル−２−オキソ−ｎ−フェニル−１，２−ジヒドロキノリン−３−カルボキサミドと、その塩及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015204932A Pending JP2016053049A (ja) | 2010-07-09 | 2015-10-16 | ５−クロロ−４−ヒドロキシ−１−メチル−２−オキソ−ｎ−フェニル−１，２−ジヒドロキノリン−３−カルボキサミドと、その塩及びその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20120010239A1 (enExample) |
| EP (2) | EP3056205A1 (enExample) |
| JP (2) | JP5934202B2 (enExample) |
| KR (1) | KR20130041193A (enExample) |
| CN (1) | CN102985090B (enExample) |
| AU (2) | AU2011274502A1 (enExample) |
| BR (1) | BR112013000607A2 (enExample) |
| CA (1) | CA2804989A1 (enExample) |
| EA (1) | EA201390074A1 (enExample) |
| HK (1) | HK1225308A1 (enExample) |
| MX (1) | MX2013000332A (enExample) |
| NZ (1) | NZ606589A (enExample) |
| WO (1) | WO2012006544A1 (enExample) |
| ZA (1) | ZA201300957B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107176923A (zh) * | 2005-10-19 | 2017-09-19 | 泰华制药工业有限公司 | 拉奎尼莫钠晶体及其制备方法 |
| KR101495327B1 (ko) | 2006-06-12 | 2015-02-24 | 테바 파마슈티컬 인더스트리즈 리미티드 | 안정한 라퀴니모드 제제 |
| US8178127B2 (en) | 2007-12-20 | 2012-05-15 | Teva Pharmaceuticals Industries, Ltd. | Stable laquinimod preparations |
| HUE026406T2 (en) * | 2009-06-19 | 2016-06-28 | Teva Pharma | Treatment of multiple sclerosis with laquinimod |
| CN105616410A (zh) * | 2009-07-30 | 2016-06-01 | 泰华制药工业有限公司 | 利用拉喹莫德治疗克隆氏病 |
| ES2731052T3 (es) | 2009-08-10 | 2019-11-13 | Active Biotech Ab | Tratamiento de la enfermedad de Huntington usando laquinimod |
| KR20150135552A (ko) | 2010-03-03 | 2015-12-02 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 루푸스 신장염의 치료 |
| WO2011109531A1 (en) * | 2010-03-03 | 2011-09-09 | Teva Pharmaceutical Industries Ltd. | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
| JP2013535437A (ja) | 2010-07-09 | 2013-09-12 | テバ ファーマシューティカル インダストリーズ リミティド | 重水素化されたｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４−ヒドロキシ−５−クロロ−１−メチル−２−オキソキノリン−３−カルボキサミド、その塩および使用 |
| SG11201401330YA (en) | 2011-10-12 | 2014-05-29 | Teva Pharma | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| US9161935B2 (en) | 2012-02-03 | 2015-10-20 | Teva Pharmaceutical Industries, Ltd. | Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy |
| AR090073A1 (es) | 2012-02-16 | 2014-10-15 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| CN103626701A (zh) * | 2012-08-28 | 2014-03-12 | 天津药物研究院 | 一种制备喹啉衍生物的方法 |
| CN103626702A (zh) * | 2012-08-30 | 2014-03-12 | 天津药物研究院 | 一种制备喹啉酮衍生物的方法 |
| CA2890194A1 (en) | 2012-11-07 | 2014-05-15 | Teva Pharmaceutical Industries Ltd. | Amine salts of laquinimod |
| WO2014153145A2 (en) | 2013-03-14 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| HK1220125A1 (zh) | 2013-03-14 | 2017-04-28 | Teva Pharmaceutical Industries Ltd. | 拉喹莫德的透皮配方 |
| UY36099A (es) | 2014-04-29 | 2016-02-29 | Teva Pharma | Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad |
| US20190090046A1 (en) * | 2017-09-21 | 2019-03-21 | Bragi GmbH | Tactile Feedback for Audio Defined Menu System and Method |
| GB202006390D0 (en) * | 2020-04-30 | 2020-06-17 | Aqilion Ab | Novel treatments |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2380420A (en) * | 1940-12-16 | 1945-07-31 | William S Emerson | Production of secondary and tertiary amines from nitrogen compounds |
| IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| DE3724018A1 (de) * | 1987-07-21 | 1989-02-02 | Bayer Ag | Verfahren zur trennung von anilin-derivaten |
| US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| SE9801474D0 (sv) * | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| US6875869B2 (en) | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US7560557B2 (en) * | 2002-06-12 | 2009-07-14 | Active Biotech Ag | Process for the manufacture of quinoline derivatives |
| SE0201778D0 (sv) * | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| CN107176923A (zh) | 2005-10-19 | 2017-09-19 | 泰华制药工业有限公司 | 拉奎尼莫钠晶体及其制备方法 |
| KR101495327B1 (ko) * | 2006-06-12 | 2015-02-24 | 테바 파마슈티컬 인더스트리즈 리미티드 | 안정한 라퀴니모드 제제 |
| US8178127B2 (en) * | 2007-12-20 | 2012-05-15 | Teva Pharmaceuticals Industries, Ltd. | Stable laquinimod preparations |
| WO2010001257A2 (en) * | 2008-07-01 | 2010-01-07 | Actavis Group Ptc Ehf | Novel solid state forms of laquinimod and its sodium salt |
| US20120009226A1 (en) * | 2008-12-17 | 2012-01-12 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
-
2011
- 2011-07-08 BR BR112013000607A patent/BR112013000607A2/pt not_active IP Right Cessation
- 2011-07-08 AU AU2011274502A patent/AU2011274502A1/en not_active Abandoned
- 2011-07-08 EA EA201390074A patent/EA201390074A1/ru unknown
- 2011-07-08 MX MX2013000332A patent/MX2013000332A/es unknown
- 2011-07-08 NZ NZ606589A patent/NZ606589A/en not_active IP Right Cessation
- 2011-07-08 CN CN201180034077.5A patent/CN102985090B/zh not_active Expired - Fee Related
- 2011-07-08 WO PCT/US2011/043391 patent/WO2012006544A1/en not_active Ceased
- 2011-07-08 CA CA2804989A patent/CA2804989A1/en not_active Abandoned
- 2011-07-08 EP EP16159268.8A patent/EP3056205A1/en not_active Withdrawn
- 2011-07-08 EP EP11804416.3A patent/EP2590653A4/en not_active Withdrawn
- 2011-07-08 US US13/178,865 patent/US20120010239A1/en not_active Abandoned
- 2011-07-08 KR KR1020137003331A patent/KR20130041193A/ko not_active Ceased
- 2011-07-08 JP JP2013519726A patent/JP5934202B2/ja not_active Expired - Fee Related
-
2013
- 2013-02-05 ZA ZA2013/00957A patent/ZA201300957B/en unknown
- 2013-05-20 HK HK16113723.9A patent/HK1225308A1/en unknown
-
2015
- 2015-10-16 JP JP2015204932A patent/JP2016053049A/ja active Pending
-
2016
- 2016-06-13 US US15/180,727 patent/US20160279121A1/en not_active Abandoned
-
2017
- 2017-11-17 AU AU2017261621A patent/AU2017261621A1/en not_active Abandoned
-
2018
- 2018-01-04 US US15/861,952 patent/US20180140592A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013534536A5 (enExample) | ||
| JP5934202B2 (ja) | ５−クロロ−４−ヒドロキシ−１−メチル−２−オキソ−ｎ−フェニル−１，２−ジヒドロキノリン−３−カルボキサミドと、その塩及びその使用 | |
| EP3135671B1 (en) | Novel crystal of tetracyclic compound | |
| JP2012521994A5 (enExample) | ||
| EP2714701B1 (en) | Process for fosaprepitant | |
| JP7447128B2 (ja) | Ａ２ａ／ａ２ｂ阻害剤としてのピラゾロピリジン及びトリアゾロピリジン | |
| JP6916207B2 (ja) | インダゾールの合成 | |
| JP2020079248A (ja) | 高純度医薬品等級タシメルテオン | |
| RU2010119458A (ru) | 1,3,5-тризамещенное производное триазола | |
| JP6842415B2 (ja) | 放射性医薬品からアセトアルデヒドを除去する方法 | |
| DK3041839T3 (en) | 1,2,4-TRIAZOLO [4,3-A] PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | |
| WO2014153145A3 (en) | Crystals of laquinimod sodium and improved process for the manufacture thereof | |
| CN105334275B (zh) | 一种枸橼酸西地那非有关物质的检测方法 | |
| CN106706818A (zh) | 一种依折麦布中间体光学纯度测定方法 | |
| CN103553996A (zh) | 抗胆碱药物组合物 | |
| JP5986635B2 (ja) | ５，６，７，８−テトラヒドロ−６−［ｎ，ｎ−ビス［（２−チエニル）エチル］］アミノ−１−ナフトール、及びその作製方法、及びその使用 | |
| JP6629740B2 (ja) | 代謝型グルタミン酸作動性受容体サブタイプ２の正のアロステリック調節因子またはオルトステリックアゴニストを含む組み合わせ、およびそれらの使用 | |
| EP3133056B1 (en) | Production method of fatty acid chloride and fatty acid chloride | |
| CN106706769B (zh) | 一种恩格列净及其光学异构体的分离测定方法 | |
| JP6684936B2 (ja) | 代謝型グルタミン酸作動性受容体サブタイプ２の正のアロステリック調節因子またはオルトステリックアゴニストを含む組み合わせ、およびそれらの使用 | |
| CN101068814A (zh) | 分离的伐昔洛韦杂质，制备伐昔洛韦杂质的方法及其作为参比标准物的应用 | |
| CN116818953A (zh) | 一种帕拉米韦起始物料及杂质a的分析方法 | |
| JP2013526577A5 (enExample) | ||
| CN101057866A (zh) | 一种可立克胶囊的制备方法 | |
| Paluch et al. | Preparation and characterisation of novel chlorothiazide potassium solid-state salt forms: Intermolecular self assembly suprastructures |